Converge Bio
Latest round
- Series A
Last raised
- Jan 2026
Total raised
- $31M
Investors
- 4
About Converge Bio
Based in Delaware, US, and founded in 2024 by co-founders Doz Gertz and Oded Kalev, Converge Bio specialises in integrating generative artificial intelligence with biological data within the biotechnology and pharmaceutical sectors. In January 2026, Converge Bio, Inc. Converge offers a comprehensive suite of products and services that leverage generative AI to enhance drug discovery and development processes in the biotech and pharmaceutical sectors. The platform integrates large language models (LLMs) specifically trained on biological data to address critical challenges such as small molecule optimisation, antibody enhancement, target discovery, vaccine design, biomarker identification, and protein engineering. By utilising advanced algorithms and a bio-LLM library, the platform improves the efficacy and safety of therapeutics. The company's client base includes biotech and pharmaceutical companies.
Who invested in Converge Bio
4 investors across 2 rounds
See all investors in Converge Bio
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Converge Bio
Who invested in Converge Bio?
Converge Bio has 4 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Converge Bio raised?
Converge Bio has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Converge Bio last raise money?
Converge Bio's most recent round on record is a Series A, in Jan 2026.
What does Converge Bio do?
Based in Delaware, US, and founded in 2024 by co-founders Doz Gertz and Oded Kalev, Converge Bio specialises in integrating generative artificial intelligence with biological data within the biotechnology and pharmaceutical sectors.
Where is Converge Bio headquartered?
Converge Bio is headquartered in Wilmington, US.
Which VCs invest in companies like Converge Bio?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Converge Bio's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Converge Bio? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.